TLRY
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Chairman
Equibles does not estimate personal net worth.
Get an email with a short summary when Stagwell Inc publishes a filing, an earnings call transcript or a press release.
Get STGW alertsIrwin Simon is recorded as CEO and Chairman at Tilray Brands, Inc. (TLRY). The newest filing on record that lists Irwin Simon as CEO at Tilray Brands, Inc. (TLRY) is dated September 28, 2026. The proxy statement of Tilray Brands, Inc. reports total compensation of $22,157,305 for Irwin Simon in fiscal 2026, including a base salary of $2,057,580. Disclosed compensation is on record for 5 fiscal years. Irwin Simon has spoken on 26 earnings calls and 1 other investor event across 1 company, most recently for Tilray Brands, Inc. on October 8, 2026. Tilray Brands, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Stagwell Inc is classified in the Advertising Agencies industry within the Communication Services sector. Other leadership on record at Tilray Brands, Inc. includes Mark Castaneda (CFO), Michael Kruteck (CFO), Jon Levin (COO) and 7 others.
“Before I discuss the quarter, I want to frame how investors should think about Tilray Brands today.”
“It's been an exciting year at Tilray Brands. We delivered a record quarter with continued international expansion across our platforms. I also want to briefly highlight our BrewDog acquisition.”
“Good afternoon for those listening internationally, and thank you for joining today's conference I'm excited to discuss the strategic acquisition of BrewDog, an iconic global brand in the beer business that will join Tilray's portfolio.”
“We delivered a strong second quarter marked by record results and a beat against analyst expectations in the face of strong headwinds. We recorded our highest ever Q2 net revenue of $218 million.”
“Thank you, Barron, and good morning, everyone, and thank you for being here for our Q1 results. Q1 fiscal 2026 was a testament to the significant momentum Tilray has built across our businesses over the years.”
Source not stated
Start not stated–present
Last confirmed September 28, 2026
TLRY
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Chairman
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Tilray Brands, Inc. (TLRY) | President, Chief Executive Officer and Chairman of the Board | $2,057,580 | $22,157,305 |
| 2025 | Tilray Brands, Inc. (TLRY) | President, Chief Executive Officer and Chairman of the Board | $1,988,000 | $10,295,612 |
| 2024 | Tilray Brands, Inc. (TLRY) | President, Chief Executive Officer and Chairman of the Board | $1,891,760 | $10,142,971 |
| 2023 | Tilray Brands, Inc. (TLRY) | President, Chief Executive Officer and Chairman of the Board | $1,819,000 | $15,656,584 |
| 2022 | Tilray Brands, Inc. (TLRY) | President, Chief Executive Officer and Chairman of the Board | $1,714,165 | $19,456,767 |